TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male and female patients aged ≥ 10 years~* Patients with transfusion-dependent thalassemia and iron overload, requiring deferasirox DT at doses of ≥ 30 mg/kg/day as per the investigator's decision OR Patients with very low, low or intermediate (int) risk myelodysplastic syndrome (MDS) and iron overload, requiring deferasirox DT at doses of ≥ 20 mg/kg/day as per the investigator's decision.~* History of transfusion of at least 20 PRBC units and anticipated to be transfused with at least 8 units of PRBCs annually during the study~* Serum ferritin \> 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the mean value will be used for eligibility criteria).~Key Exclusion Criteria:~* Creatinine clearance below the contraindication limit in the locally approved prescribing information. Creatinine clearance will be estimated from serum creatinine at screening Visit 1 and screening Visit 2 and the mean value will be used for eligibility criteria.~* Serum creatinine \> 1.5 xULN at screening measured at screening Visit 1 and screening Visit 2 (the mean value will be used for eligibility criteria).~* ALT (SGPT) \> 5xULN, unless LIC confirmed as \>10 mg Fe/dw within 6 months prior to screening visit 1.~* Significant proteinuria as indicated by a urinary protein/creatinine ratio \> 0.5 mg/mg in a non-first void urine sample at screening Visit 1 or screening Visit 2.~* Patients with significant impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).~* Liver disease with severity of Child-Pugh Class B or C

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox dispersible tablet (DFX-DT) (Type: ACTIVE_COMPARATOR): Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.
- Deferasirox film-coated tablet (DFX-FCT) (Type: EXPERIMENTAL): Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* To be enrolled in the study, participants must be between the ages of 18-40 years (younger groups) or \> 50 years (older groups); our goal is to recruit at least 50% of older HIV+ participants who are \> 60 years old.~* Eligible participants must have documented presence or absence of HIV infection (depending on their group assignment), based on serologic testing for HIV antibody (screening ELISA, confirmed by Western blot if positive).~* The documentation of HIV status will be obtained once informed consent has been established.~Exclusion Criteria:~* CNS infection other than HIV (no opportunistic CNS disease)~* CNS neoplasm, neurosyphilis~* traumatic brain injury with loss of consciousness greater than 30 minutes~* current diagnosis of seizure disorder, current psychotic spectrum disorders (e.g., schizophrenia, bipolar disorder)~* history of drug or alcohol abuse or dependence within the past year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: None): HIV-positive adults 50 and older/ HIV-positive adults 18-40 years old
- Group 2 (Type: None): HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
- Group 3 (Type: None): HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
- Group 4 (Type: None): HIV-negative controls 18-40 years old

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HIV-1 infection.~* Documented level of HIV-1 RNA at initiation of antiretroviral treatments~* Prior antiretroviral regimen, including at least 2 NRTIs combined to 1 PI or NNRTI or a third NRTI for at least 18 months prior to study entry.~* CD4 count of 200 cells per mm3 or greater.~* Viral load below 400 copies per ml within 18 months prior to entry and below 50 copies per mL at entry.~* Willing to use acceptable methods of contraception~Exclusion Criteria:~* Previous virological failure under prior PI-based regimen.~* Prior therapy in the darunavir.~* HIV-2 infected patients.~* Absence of documented level of HIV-1 RNA at initiation of antiretroviral treatments~* Hepatitis B or C infection within 90 days prior to study entry.~* Therapies including interferon, interleukin-2, cytotoxic chemotherapy or immunosuppressors at study entry.~* Serious acute illness requiring systemic treatment or hospitalization in the 14 days prior to study entry.~* Treatment for an active AIDS defining opportunistic infection within 30 days prior to screening~* Drug or alcohol use or any dependence that would interfere with compliance.~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria :~* Signed patient informed consent;~* Type 2 diabetes mellitus;~* Treated with at least 1 oral antidiabetic drug (OAD) for at least 6 months;~* Hemoglobin A1c (HbA1c) \>7.0 % and ≤11% within 3 months of study baseline;~* Physicians' decision in accordance with the current local guidelines to add basal insulin glargine U300 to an existing OAD regimen~Exclusion criteria:~* Diabetes mellitus other than type 2;~* Contraindication to insulin glargine U300 according to local product labelling;~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (U300) (Type: None): Insulin glargine (U300) dosage and dosing time as per local product labeling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Engagement to Care South Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HIV positive (diagnosed within the last 12 months prior to study/patient contact)~* Has access to a mobile phone~* Willing to receive and respond to text messages and calls from clinic and study staff (all arms)~* Willing to communicate and meet with PN (PN arm)~* Willing to meet with study staff for survey at study start, 6 months, and 12 months (all arms)~* regard study clinic area as the regular clinic for accessing healthcare~Exclusion Criteria:~* First tested positive over 12 months prior to recruitment~* Under the age of 18~* Unable to give informed consent~* Unable to read basic English and with no one to read study sms to participant~* Principally accesses care through a clinic not in the study~* Planning to permanently move away from the area served by the clinic within next 6 months (following enrollment)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime) only. This group will not receive any additional engagement to care intervention.
- SMS text message (Type: ACTIVE_COMPARATOR): Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also automated bi-weekly check-in text messages that will trigger a phone call from clinic staff if the participant reports not being well.
- SMS text message + Peer Navigation (Type: ACTIVE_COMPARATOR): Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also bi-weekly contact from an HIV-positive peer who provides personalized support and with health or other service systems navigation assistance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxytocin Via Intramuscular Injection and Intravenous Bolus or Infusion for Prevention of Postpartum Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All women who present in active labor for a live birth at the study hospital will be considered for participation in the study~Exclusion Criteria:~* Planned or transferred for delivery via Cesarean section~* Administration of a pre-delivery uterotonic to induce or augment labor~* Unable to provide informed consent due to mental impairment, distress during labor or other reason

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- IV infusion (Type: ACTIVE_COMPARATOR): Oxytocin 10 IU will be administered by IV infusion according to randomization assignment as soon as possible after delivery of the baby.
- IV bolus (Type: ACTIVE_COMPARATOR): Oxytocin 10 IU will be administered by IV bolus according to randomization assignment as soon as possible after delivery of the baby.
- IM injection (Type: ACTIVE_COMPARATOR): Oxytocin 10 IU will be administered by IM injection according to randomization assignment as soon as possible after delivery of the baby.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has documented chronic HCV GT1, GT4, or GT6 (with no evidence of non-typeable or mixed genotype) infection~* Meets clinical criteria for presence or absence of cirrhosis based on liver disease staging assessment~* Is abstinent or uses acceptable method(s) of contraception~Exclusion Criteria:~* Has evidence of decompensated liver disease~* Is coinfected with hepatitis B virus or human immunodeficiency virus (HIV)~* Shows evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC~* Has a clinically-relevant drug or alcohol abuse within 12 months of screening~* Is pregnant or breast-feeding~* Has any condition or abnormality that might confound the results of the trial or pose an additional risk to the participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Treatment Group (ITG): Grazoprevir/Elbasvir (Type: EXPERIMENTAL): Participants receive a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth during a 12-week Active Treatment period (Week 1 to Week 12) and are followed-up for 24 weeks to Week 36.
- Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir (Type: PLACEBO_COMPARATOR): Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C virus (HCV) infection~* Screening laboratory results indicating HCV genotype 1 - 6 (GT1 - 6) infection.~* Subject must be HCV treatment-naïve or have failed previous HCV treatment.~* Subjects with underlying chronic renal impairment (estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 as estimated by the MDRD method at screening, including those requiring dialysis).~* Non-cirrhotic subjects must have documented absence of cirrhosis and subjects with cirrhosis must have documented compensated cirrhosis.~Exclusion Criteria:~* History of severe, life-threatening or other significant sensitivity to any excipients of the study drug.~* Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.~* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.~* Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).~* HCV genotype performed during screening indicating co-infection with more than 1 HCV genotype; HCV GT3 infected, treatment-experienced subjects were excluded.~* Patients who failed a previous regimen containing protease inhibitor (PIs) and/or nonstructural protein 5A (NS5A) inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-493/ABT-530 (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with mixed dyslipidemia~* Subjects must agree to utilize adequate birth control methods and to adhere to the American Heart Association (AHA) diet~Exclusion Criteria:~* Subjects with unstable medical conditions or medical conditions considered inappropriate in a clinical trial.~* Patients who are taking certain medications or unstable dose of specific medications.~* Women who are pregnant or plan on becoming pregnant, or women who are lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): ABT-335 + 20 mg atorvastatin
- B (Type: ACTIVE_COMPARATOR): ABT-335 + 40 mg atorvastatin
- C (Type: PLACEBO_COMPARATOR): ABT-335 monotherapy
- D (Type: PLACEBO_COMPARATOR): 20 mg atorvastatin monotherapy
- E (Type: PLACEBO_COMPARATOR): 40 mg atorvastatin monotherapy
- F (Type: PLACEBO_COMPARATOR): 80 mg atorvastatin monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female patient 50 years of age or older; diagnosis of COPD; current or ex-smoker with at least 10 pack-years of smoking; a patient-reported score for breathlessness during activities of daily living of \< 9 on the self-administered computerized baseline dyspnea index; a post-bronchodilator FEV1 \< 80% predicted; a post-bronchodilator FEV1/FVC ratio \< 70%; and clinically stable condition.~Exclusion Criteria:~* any concomitant disease that interferes with study procedures or evaluation; inability to exercise on the treadmill or cycle ergometer; inability to withhold short-acting bronchodilators for 4 hours or long-acting bronchodilators for 12 hrs (salmeterol or formoterol) and for 24 hours (tiotropium) prior to testing

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arformoterol tartrate (Type: ACTIVE_COMPARATOR): Bronchodilator therapy with arformoterol solution 15 mcg
- Normal saline (Type: PLACEBO_COMPARATOR): Placebo using normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight 40 kg--150 kg~* Chest radiograph with no evidence of clinically significant abnormality~* Uncontrolled asthma~Exclusion Criteria:~* Asthma exacerbation during screening~* Known malignancy~* Known immunodeficiency~* Pre-existing lung disease other than asthma~* Uncontrolled clinically significant medical disease~* Current smoker~* History of substance abuse that may impair or risk the patient's full participation in the study, in the judgment of the investigator~* Prior allergic reaction to a monoclonal antibody~* Patients (men and women) of reproductive potential who are not willing to use contraception~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of endogenous anterior uveitis in at least 1 eye.~* The presence of \> 10 cells in the anterior chamber of at least one eye, and a flare score of \> 2 in that same eye.~* Age 2 years or older on day of consent.~* Negative urine pregnancy test on Day 0 for females of childbearing potential who are not at least 1 year post-menopausal or surgically sterilized.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Presence of endogenous anterior uveitis diagnosed for \> 2 weeks prior to enrollment in the study.~* Presence of intermediate uveitis, posterior uveitis or panuveitis in either eye.~* Instillation of any topical corticosteroid or NSAID in the study eye within 7 days of instillation of study drug.~* History of glaucoma or clinically significant ocular hypertension in the opinion of the Investigator involving an IOP ≥ 21 millimeters mercury in either eye.~* History of steroid-induced elevation of intraocular pressure.~* Any confirmed or suspected active viral, bacterial or fungal keratoconjunctival disease in either eye.~* History of glaucoma or clinically significant ocular hypertension in the opinion of the Investigator involving an intraocular pressure (IOP) \> 21 mmHg in either eye.~* Corneal abrasion or ulceration in either eye.~* Pregnancy or lactation.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Durezol (Type: EXPERIMENTAL): Difluprednate 0.05% ophthalmic emulsion, 1 drop in study eye, 4 times a day for 14 days, followed by a 14-day tapering period
- Pred Forte (Type: ACTIVE_COMPARATOR): Prednisolone acetate 1.0% ophthalmic suspension, 1 drop in study eye, 8 times a day for 14 days, followed by a 14-day tapering period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete